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a  b  s  t  r  a  c  t
Bluetongue  (BT)  is a  hemorrhagic  disease  of  ruminants  caused  by bluetongue  virus  (BTV),  the prototype
member  of  the genus  Orbivirus  within  the family  Reoviridae  and  is  transmitted  via biting  midges  of  the
genus  Culicoides.  BTV  can be found  on  all continents  except  Antarctica,  and  up  to  26 immunologically
distinct  BTV  serotypes  have  been  identiﬁed.  Live  attenuated  and inactivated  BTV  vaccines  have  been used
over  the years  with  different  degrees  of  success.  The  multiple  outbreaks  of  BTV  in  Mediterranean  Europe
in  the  last  two decades  and  the incursion  of  BTV-8  in  Northern  Europe  in  2008  has  re-stimulated  theeterotypic protection
interest  to  develop  improved  vaccination  strategies  against  BTV.  In  particular,  safer,  cross-reactive,  more
efﬁcacious  vaccines  with  differential  diagnostic  capability  have been  pursued  by multiple  BTV  research
groups  and  vaccine  manufacturers.  A  wide  variety  of recombinant  BTV  vaccine  prototypes  have  been
investigated,  ranging  from  baculovirus-expressed  sub-unit  vaccines  to  the  use of  live viral  vectors.  This
article  gives  a brief  overview  of  all these  modern  approaches  to  develop  vaccines  against  BTV  including
some  recent  unpublished  data.© 2013  The  Authors.  Published  by  Elsevier  B.V. 
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. Introduction
Open access under CC BY license.Bluetongue virus (BTV) was ﬁrst detected in 1900, when Merino
heep were imported into South Africa and became infected
∗ Corresponding author at: The Pirbright Institute, Pirbright, Surrey GU24 0NF,
nited Kingdom. Tel.: +44 01483 231081.
E-mail address: javier.castillo-olivares@pirbright.ac.uk (J. Castillo-Olivares).
168-1702  © 2013 The Authors. Published by Elsevier B.V. 
ttp://dx.doi.org/10.1016/j.virusres.2013.11.013
Open access under CC BY license.(Spreull, 1905) showing clinical signs of hemorrhagic disease. This
virus belongs to the Orbivirus genus, within the family Reoviri-
dae and has a double stranded RNA genome that encodes four
non-structural (NS1–NS4) and seven structural proteins (VP1–VP7)
(Mertens et al., 1984; Mertens, 1986). The genome segments are
packaged within an icosahedral capsid, ∼80 nm in diameter, com-
posed of three concentric protein layers. The innermost ‘subcore’
shell is constructed from 12 decamers of VP3, surrounding the virus
genome and viral transcriptase complexes, and provides a ‘scaffold’
for addition of 780 copies of VP7 (organized as 260 trimers) to form
the core-surface layer. The addition of 60 trimers of VP2 and 120
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rimers of VP5 which form the outer capsid layer, complete the
irion structure (Roy, 1989).
The efﬁcient transmission of the virus by Culicoides midges in
reas with suitable vector species results in a fast spread of the
isease. The disease has been devastating for European cattle and
heep especially since 1998 after repeated BTV outbreaks caused
y 6 of the 26 different serotypes (Darpel et al., 2007; Maan et al.,
012). This has resulted in a big impact on trade and agriculture,
aking very important the development of new safe and effective
accines against the virus.
Modiﬁed live vaccines have long been used to control BT in
heep in southern Africa, and more recently in Corsica, the Balearic
slands and Italy (Savini et al., 2008). Although live attenuated vac-
ines appear to be effective for protection of individual susceptible
nimals against clinical signs of bluetongue, they are teratogenic
nd cause other adverse effects (IZSAM, 2001; Veronesi et al., 2010).
oreover, the vaccine virus can be detected in blood after vacci-
ation and reaches titers that are compatible with transmission
o other mammalian hosts via Culicoides midges (Elia et al., 2008).
hen vaccine virus is transmitted to unvaccinated animals (Ferrari
t al., 2005; Savini et al., 2008) there is a further risk of genome
egment re-assortment between vaccine and ﬁeld strains, lead-
ng to the emergence of new strains with unpredictable biological
haracteristics (Batten et al., 2008).
Whole inactivated virus vaccines represent a safer alternative to
ive attenuated vaccines and are commercially available but some
oncerns exist over the reliability of inactivation for each vaccine
atch (Gethmann et al., 2009). Inactivated BTV vaccines have pre-
ented the re-emergence of the disease in northern Europe in the
ears that followed the 2008 outbreak, however the cost of pro-
uction of inactivated vaccines is high and various boosters are
ecessary to achieve solid immunity.
Serological screening techniques are essential for the surveil-
ance of the disease in non-endemic countries when a vaccination
ampaign is followed and to demonstrate freedom of the disease
nce the outbreak has ended. There is currently not a reliable sero-
ogical test to “distinguish infected from vaccinated animals” (DIVA
ssays) when either inactivated or attenuated BTV vaccines are
sed. For these reasons the development of recombinant BTV vac-
ines, which are inherently safer, and are based on selected BTV
ntigens and are therefore compatible with a DIVA approach, has
een the subject of research over more than two decades. This
eview describes novel advances in the development of recombi-
ant vaccines against BTV and the different studies testing their
rotective efﬁcacy.
. New-generation vaccines against BTV
Different strategies have been followed over the last 3 decades
o develop novel recombinant vaccines for BTV, ranging from
aculovirus expressed sub-unit vaccines to live virus vector vac-
ines (Table 1).
Immunological studies to date have given many clues about
hat BTV proteins are more important to induce protective
able 1
ecombinant viral vector vaccines against BTV tested in IFNAR (−/−) mice.
Delivery viral vector Proteins expressed Protect
Bovine herpes virus VP2 BTV-8 Partial
Equine  herpes virus VP2 BTV-8 No 
Equine  herpes virus VP2, VP5 BTV-8 Partial
MVA  virus VP2, VP5 BTV-4 Partial
MVA  virus VP2, VP5, VP7 BTV-4 Compl
MVA  virus VP2, VP5, VP7 BTV-4 Compl
MVA  virus VP7, NS1 BTV-4 Partial
MVA  virus VP2, VP5, VP7 BTV-8 Compl
MVA  virus VP2 BTV-8 Complearch 182 (2014) 78–86 79
host immune responses against the virus. The cellular receptor
binding protein VP2 induces serotype speciﬁc neutralizing anti-
bodies (Huismans and Erasmus, 1981) and protective immunity
(Huismans et al., 1987). Epitope mapping studies revealed that the
major virus neutralizing epitopes are located in the protein VP2
(Roy, 1992). This protein is the most variable protein among BTV
serotypes and is the determinant of the serotype (Mertens et al.,
1989). Antibodies raised against VP2 can sometimes neutralize,
although less efﬁciently, other very closely relates serotypes (Roy,
1992). However 26 serotypes of BTV have been reported (Maan
et al., 2012) and low levels of cross-protection are described, com-
plicating vaccination strategies. VP5 protein is the second most
variable of the BTV proteins and seems to exert some inﬂuence in
the conformation of VP2 (Cowley and Gorman, 1989; Mertens et al.,
1989). It has been demonstrated that both virus neutralizing anti-
body responses (Jeggo et al., 1984b) and cytotoxic T-lymphocytes
(CTL) have a main role in protective immunity against BTV (Jeggo
and Wardley, 1982; Jeggo et al., 1984a). BTV-speciﬁc CTL have been
studied in sheep, describing VP2 and NS1 as major CTL targets
(Andrew et al., 1995). NS1 was recognized by CTL from all Merino
sheep immunized with recombinant vaccinia viruses, while VP2,
VP3, VP5 and VP7 were recognized by CTL from only some sheep
(Janardhana et al., 1999). In mice, statistical analysis of the CTL
responses indicated that non-structural protein peptides were the
predominant source of homotypic and heterotypic CTL recognition
(Jones et al., 1996). In mice, T-cell epitopes (CD4 and CD8) were
identiﬁed in the major BTV group-reactive antigen VP7 and these
epitopes were also recognized by cells from BTV infected sheep
(Rojas et al., 2011).
In general, vaccine approaches developed against viral dis-
eases are preferably tested in a natural host. However, constraints
imposed by the high cost of performing experiments in
bio-containment facilities for large animals have led to the estab-
lishment of a small animal model for BTV (Calvo-Pinilla et al.,
2009a). This murine model based on adult IFNAR (−/−) mice facil-
itates the study of the BTV immune responses and the testing
of new vaccines against bluetongue. IFNAR (−/−) mice are lack
the -subunit of the interferon / receptor and this model has
been used successfully in various studies with orbiviruses (Calvo-
Pinilla et al., 2010; Castillo-Olivares et al., 2011; Eschbaumer et al.,
2012).
2.1. Subunit vaccines
Protein-based vaccines against BTV have been developed using
single proteins or by combining various proteins in the same vac-
cine preparation. Huismans et al. (1987) isolated VP2 from puriﬁed
BTV by chemical means using divalent salts. Vaccination of sheep
with this protein induced virus neutralizing antibodies and protec-
tion against virulent homologous challenge (Huismans et al., 1987).
Despite its efﬁcacy, this strategy could not be developed further due
to the large amounts of virus required to produce enough puriﬁed
protein for use in a sub-unit vaccine formulation.
ion homologous challenge Protection heterologous challenge
 Not analyzed
Not analyzed
 Not analyzed
 Not analyzed
ete No
ete Complete
 Partial
ete Not analyzed
ete Not analyzed
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gene delivery systems for BTV-vaccination with different levels of
success (Boone et al., 2007; Calvo-Pinilla et al., 2009b; Franceschi
et al., 2011; Ma et al., 2012; Savini et al., 2008). In general, vector0 E. Calvo-Pinilla et al. / Vir
Following Huismans ﬁndings, Roy and co-workers developed
 sub-unit vaccination strategy based on the expression of BTV
roteins using recombinant baculovirus systems (Roy, 1990).
TV proteins derived individually from baculovirus vectors were
dministered in different combination and doses to sheep and pro-
ection was evaluated against homologous challenge with virulent
TV-10 (Roy et al., 1990). A minimal dose of 100 g of VP2 was
eeded to protect sheep against challenge. However, when used in
ombination with 20 g of VP5, a lower dose of VP2 (50 g) was
ufﬁcient to elicit equivalent virus neutralizing antibody titers and
o protect immunized sheep against BTV infection. This increased
esponse was thought to be due to the synergistic effect of the
wo proteins. In these studies, the addition of VP1, VP3, VP6, VP7,
S1, NS2 and NS3 proteins to the VP2/VP5 based vaccines did not
nhance the neutralizing antibody response but also protected all
heep.
The most successful subunit vaccines against BTV are based in
he co-expression of the four major structural proteins of the virus
VP2, VP5, VP3 and VP7), which results in their assembly into “virus
ike particles” (VLPs). VLPs were ﬁrst developed in 1990 for BTV-10
Roy, 1990) and since then this approach has been used to pro-
uce VLPs from a variety of BTV serotypes. VLPs from BTV-10 or
TV-17 or from ﬁve serotypes in combination (BTV-1, BTV-2, BTV-
0, BTV-13 and BTV-17) were tested in vaccination studies and
aised speciﬁc neutralizing antibodies and a protective response
n sheep against homologous challenge (Roy et al., 1994). Neutral-
zing antibody titers in animals that received doses of 50 g of VLPs
ere not signiﬁcantly higher than those vaccinated with 10 g.
his work also demonstrated that vaccination with VLPs from BTV-
0 and BTV-17 induced neutralizing antibodies against the related
based on the amino-acid sequence of VP2) BTV-4, and partial pro-
ection was afforded against this heterologous serotype (Roy et al.,
994). Later on, another study described that again VLPs from BTV-8
ere able to afford complete protection against a homologous viral
hallenge in sheep (Stewart et al., 2013). This approach was  also
ffective in combination with VLPs from BTV-1 or BTV-2. Additional
tudies described homologous protection in sheep using VLPs from
TV-1 and interestingly in this case the protection was  afforded
gainst a virulent virus from a different geographic origin (Stewart
t al., 2012).
Summarizing all these experiments with VLPs, a dose of BTV
LPs of 10 g in combination with adjuvant afforded protection
gainst virulent virus challenge. Both incomplete Freunds’ adju-
ant and an incomplete Montanide ISA-50 adjuvant proved to
ncrease the immune response against BTV VLPs (Roy et al., 1992).
uch lower doses of VP2 antigen were needed when VP2 was pre-
ented in the context of a VLP vaccine than when used alone as
 sub-unit vaccine. Thus, just 2.39 g of VP2 contained in 10 g
f VLP was necessary to achieve complete protection against chal-
enge, whereas 100 g of single VP2 were needed to achieve the
ame effect (Roy et al., 1990; Roy, 2002). It was proposed that
he presence of other capsid proteins in the VLP had an inﬂu-
nce in the conformation and folding of VP2 and therefore the
orrect presentation of virus neutralizing epitopes of this protein.
his hypothesis is consistent with the ﬁnding that 50 g of VP2 is
nly protective if co-administered with 20 g of VP5 (Roy et al.,
990).
Additional studies using baculovirus expressed antigens
howed that co-expression of VP3 and VP7 proteins resulted in the
eneration of “core like particles” (CLPs). Vaccination studies with
hese CLPs however did not induce complete immunity against BTV
Stewart et al., 2012; Thuenemann et al., 2013) suggesting that VP2
nd possibly VP5 are essential components of a potential sub-unit
TV vaccine.
VLPs of BTV have been also produced in plants recently using the
owpea mosaic virus and their use in a vaccination study producedearch 182 (2014) 78–86
no clinical manifestations in sheep after homologous challenge,
although viremia was no evaluated (Thuenemann et al., 2013).
Bacterial and yeast expression systems to produce recombi-
nant BTV proteins have also been developed for several authors
(Gould et al., 1994; Martyn et al., 1994; Pathak et al., 2008). Jab-
bar and co-workers expressed VP2, VP5 and VP7 proteins of BTV-8
by bacterial expression system and were tested as subunit vac-
cine in IFNAR (−/−) mice (unpublished). In this study, VP2 protein,
either as a complete protein or as three separate overlapping frag-
ments; and full-length VP5 and VP7 were expressed and used in
vaccination experiments. When IFNAR (−/−) mice were vaccinated
with fragmented VP2 together with VP5 and VP7 (with Montanide
ISA-50V adjuvant), no neutralizing antibodies were induced and
no protection was  achieved after infection with 100 pfu of BTV-8.
However when mice were vaccinated with complete VP2 together
with VP5 and VP7 (also with Montanide), partial protection was
observed against BTV-8 challenge since clinical score, mortality
rates (50%) and viremia were lower than in the unvaccinated con-
trol mice. Vaccinated animals with complete BTV proteins showed
neutralizing antibody response, albeit at low levels. It was sug-
gested that the insolubility of the proteins used in the experiment
may have had an effect on the lack of complete efﬁcacy of the
vaccination.
2.2. DNA vaccines
DNA vaccines have advantages as safety, easy manufacturing,
biological stability and cost effectiveness. In the case of BTV, this
vaccination approach was  tested in our laboratory and it provided
partial protection when plasmids expressing VP2, VP7 and NS1 pro-
teins from BTV-4 were used in combination to vaccinate IFNAR
(−/−) mice (unpublished). Mice were vaccinated twice with 50 g
of each plasmid two  weeks apart and challenged with 106 pfu
of BTV-4. Although there was  no clinical protection, viremia was
delayed in DNA-BTV immunized animals in comparison with non-
immunized animals.
Although DNA vaccines often have low immunogenicity, they
can be useful to prime the immune system when used in heterolo-
gous vaccination regimes in combination with recombinant viruses
as boosting agents. This heterologous vaccination strategy was  suc-
cessfully used in various studies (Calvo-Pinilla et al., 2009b, 2012;
Jabbar et al., 2013).
2.3. Recombinant viral vector vaccines
These vaccines are based on recombinant viruses that carry
genes encoding BTV antigens for their expression in the host upon
inoculation. Immunity induced by recombinant viral vaccines is
normally attributed to the capacity of the recombinant virus to
express the gene of interest at high levels within cells of the host.
The viral vectors used for this purpose are attenuated to the host
and are therefore inherently safe and because they carry the trans-
genes of interest devoid of other molecular regulatory elements
of the parental virus the risk of gene segment re-assortment with
ﬁeld bluetongue strains is highly reduced. Viruses such as canary-
pox, capripox, vaccinia and herpes virus have all been tested asvaccines expressing BTV VP2 have been the most successful, elic-
iting protective immune responses in animals against homologous
challenge, which is consistent with the data obtained from protein
based vaccines (Tables 1 and 2).
E. Calvo-Pinilla et al. / Virus Research 182 (2014) 78–86 81
Table  2
Recombinant viral vector vaccines against BTV tested in sheep.
Delivery viral vector Proteins expressed Protection homologous challenge Protection heterologous challenge
Capripox virus VP7 BTV-1 Not analyzed Partial
Capripox virus VP2, VP7, NS1, NS3 BTV-2 Partial Not analyzed
Canarypox virus VP2, VP5 Complete Not analyzed
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Vaccinia virus WR VP2, VP5 
MVA  virus VP2, VP7, NS1 BTV-4 
.3.1. Herpes viruses
Herpes viruses have been used extensively in gene therapy
pplications since these large enveloped double stranded DNA
iruses can accommodate large foreign gene inserts. Bovine and
quine herpes viruses have been used to construct recombinant
ectored vaccines against BTV-8 achieving partial protection in
accination-challenge experiments in IFNAR (−/−) mice.
.3.1.1. Bovine herpes virus. A non-pathogenic strain of bovine
erpes virus 4 cloned as a bacterial artiﬁcial chromosome (BAC-
oHV-4-A) was used to generate a recombinant BoHV-4 expressing
TV-VP2. The protective efﬁcacy of BoHV-4-VP2 was  tested in the
FNAR (−/−) mouse model (Franceschi et al., 2011). In this study, 6
ice were vaccinated two weeks apart with 106 pfu BoHV-4-VP2
nd virus neutralizing antibodies were detected at a 1:10 serum
ilution in all mice and at a 1:20 serum dilution in 50% of the ani-
als. Two weeks after second vaccination, mice were challenged
ith 10 pfu of BTV-8. Both clinical signs and viremia were delayed
y 5 days in the immunized animals in comparison with the con-
rol mice. One vaccinated mouse remained alive until the end of
he experiment, indicating that the 17% of the vaccinated animals
ere completely protected. Therefore, the BoHV-4-VP2 was  capa-
le of elicited partial protection against homologous BTV in this
ouse model.
.3.1.2. Equine herpes virus type 1. In a more recent study, an equine
erpes virus (EHV) was used as a vaccine delivery system of VP2 and
P5 from BTV-8 (Ma  et al., 2012). The EHV-1 strain RacH has been
stablished as an infectious bacterial artiﬁcial chromosome (BAC),
aking easy the manipulation of the virus genome. Live-vectored
accines based on the RacH strain have been developed against sev-
ral viruses and were shown to provide protection against disease
ince they induce both humoral and cellular immune responses
Rosas et al., 2007, 2008; Said et al., 2011). Two EHV-1 RacH-based
ecombinant vaccines expressing the immunodominant outer cap-
id protein VP2 of BTV-8, either alone (rH VP2) or in combination
ith VP5 (rH VP2 VP5) were evaluated in the IFNAR (−/−) mouse
odel against homologous challenge with 5 × 103 pfu of BTV-8.
mmunization with two  doses of 106 pfu of rH expressing VP2 alone
id not protect mice against BTV-8 challenge. Although the course
f the disease was slightly delayed in rH VP2 vaccinated mice in
omparison with the control group all vaccinated mice died by day
 after challenge infection. In contrast, a higher degree of protection
as observed when VP2 and VP5 were used in combination. Mice
mmunized twice with the rH VP2 VP5 only transiently displayed
ild disease (stilted gait, rufﬂed coat) and weight loss (about 5%),
ut fully recovered by day 9.
.3.2. Poxviruses
Like herpesvirus vectors, poxviruses can accommodate largeragments of foreign DNA but poxvirus replication occurs within
he cytoplasm of infected cells, eliminating the risk of virus per-
istence and genomic integration in host DNA. Various members
f the family Poxviridae have been used as to express BTV antigens.
he most widely used are capripox, canarypox and vaccinia viruses.l Not analyzed
l Not analyzed
nalyzed Partial
2.3.2.1. Capripox. A recombinant capripox virus (rCPV.BTV1.VP7)
expressing VP7 from the BTV-1 South Africa strain (BTV-1SA) was
generated by cloning the segment 7 of BTV-1SA into the plasmid
pCR-3 under the control of the late vaccinia promoter p11. The
capripox virus thymidine kinase (TK) DNA sequences ﬂanking the
BTV segment 7 in the plasmid enabled the integration of the expres-
sion cassette, via homologous recombination, into viral genome of
the KS-1 capripox vaccine strain viral at the TK locus. In order to
test the efﬁcacy of this vectored vaccine, eight lambs were vac-
cinated with 1.5 × 107 pfu of rCPV.BTV1.VP7 and four lambs were
vaccinated with the KS-1 vaccine strain. All animals vaccinated with
rCPV.BTV1.VP7 showed a signiﬁcant titer of antibodies against VP7
as measured by ELISA in contrast to animals vaccinated with the
KS-1 vaccine strain. However, the virus neutralizing antibody titers
were negative until challenge. All vaccinated animals and unvac-
cinated controls were challenged 5 weeks post-vaccination with a
lethal dose of BTV-3. All KS-1 vaccinated and the non-vaccinated
lambs died. Mortality of the rCPV.BTV1.VP7 vaccinates was  reduced
to 25%. The rest of vaccinated animals fully recovered at week four
post-vaccination. It was  proposed that the partial cross-protection
observed was  mediated by cell-mediated immunity against VP7
(Wade-Evans et al., 1996).
Additional vaccination studies have been carried out with other
recombinant capripox viruses expressing VP2, VP7, NS1 and NS3
proteins of BTV-2 (Perrin et al., 2007). All those genes were
cloned individually into pKSCATpSGPT under the early/late syn-
thetic vaccinia promoter PS and recombinant capripox viruses were
generated by homologous recombination of the expression cas-
sette into the TK locus of the KS-1 capripox virus strain. Sheep
were inoculated either with 2 × 106 TCID50 of each recombinant
capripox or a recombinant capripox expressing haemagglutinin of
the peste des petits ruminants virus (PPRV) as control. Animals vac-
cinated with recombinant capripox expressing either NS3, VP7 or
VP2 developed an antibody response against the transgenes. The
NS1 capripox failed to do so. When animals were challenged with
104 TCID50 of BTV-2, all vaccinated and non-vaccinated animals
developed viremia. However there was a delay in the detection of
BTV genome by RT-PCR in immunized sheep. One animal out of 11
died in the BTV-Cpox group whereas 3 animals out of 10 died in the
negative control group. Herein capripox viruses expressing VP2,
VP7, NS1 and NS3 proteins conferred partial protection in sheep
against homologous challenge.
2.3.2.2. Canarypox. Recombinant canarypox expressing VP2 and
VP5 proteins have also been tested as potential vaccines for BTV
(Boone et al., 2007). Segments 2 and 5 from BTV-17 were cloned in
the same plasmid transfer vector under two  different poxvirus pro-
moters ﬂanked by the canarypox C5 DNA sequences which enabled
the insertion of the dual expression cassette into the C5 locus of
canarypox virus. Six sheep were vaccinated with the recombinant
canarypox expressing VP2 and VP5 (BTV-CP) and 5 sheep were vac-
cinated with recombinant canarypox expressing proteins of West
Nile virus (WNV-CP) as control. Prime boost vaccination induced
speciﬁc BTV-17 neutralizing antibodies in BTV-CP group at week 4.
After challenge with 105.5 TCID50 of BTV-17 at day 34, none of the
vaccinated animals showed clinical signs or viremia, even 2 out of 6
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nimals did not seroconvert to VP7 after challenge, suggesting that
he replication of the virus were not enough to produce antibodies
gainst this protein. The control group showed clinical signs at 6
ays after challenge and high viremia was detected.
.3.2.3. Vaccinia virus. The ﬁrst trial of Vaccinia virus as vaccine
gainst BTV was in 1997, using a recombinant vaccinia virus WR
train, that expressed both VP2 and VP5 (VV-VP2-VP5) or VP2 alone
VV-VP2) of Australian BTV serotype 1, although this approach has
ot been pursued further. The vaccination induced variable titers
f neutralizing antibody in sheep and afforded partial protection
gainst homologous challenge with no detectable viremia in all
heep immunized with VV-VP2 and 66% of sheep vaccinated with
V-VP2-VP5 (Lobato et al., 1997).
.3.2.4. Modiﬁed Vaccinia Ankara. Subsequent studies using Vac-
inia as a recombinant viral vaccine vector were based on Modiﬁed
accinia Ankara (MVA). This virus was obtained from the Chorioal-
antois vaccinia virus Ankara which was passaged over 570 times
n cell culture. As a result, MVA  lost 15% of the parental genome
nd replication deﬁcient in humans and most mammalian cells
Esteban, 2009; Mayr et al., 1978). Recombinant MVA  (rMVA)
xpressing immunogenic viral proteins has been shown to induce
oth humoral and cell mediated immunity (Ramirez et al., 2000).
his attenuated virus has a well-established safety record and his-
ory of use as a vaccine for infectious diseases (Esteban, 2009;
ennedy and Greenberg, 2009).
MVA  has been used to construct many vectored vaccines
xpressing different proteins from different BTV serotypes. The
ransfer plasmid pSC11 has been used in all cases to clone the
TV genes of interest under the control of the vaccinia virus (VV)
arly/late promoter p7.5. Finally recombinant MVAs were gener-
ted after homologous recombination in cells between the TK gene
equences of pSC11 and those of wild type MVA  virus. All of these
ecombinant vectors have been tested in IFNAR (−/−) mice and very
ecently one of the approaches has been also tested in sheep.
Initial vaccination studies in IFNAR (−/−) mice with recombi-
ant MVA  virus (rMVA) expressing BTV-4 antigens were performed
sing a plasmid DNA (pcDNA3) prime-rMVA boost vaccination
egime. This heterologous vaccination regime was chosen since
NA priming has been described to improve the expansion of spe-
iﬁc primed immune cells. In these experiments the dose of each
MVA used in vaccination was 107 pfu per mouse and the dose of
ach DNA used was 50 g per mouse (Calvo-Pinilla et al., 2009b;
012).
Thus, IFNAR (−/−) mice inoculated with DNA-VP2-VP5 and
oosted with rMVA-VP2-VP5 generated high levels of neutral-
zing antibodies against BTV-4. After a lethal challenge with
03 pfu/mouse of BTV-4, the appearance of viremia was  delayed in
accinated animals and their highest viremia levels were 10-fold
ower than in infected non-immunized mice. Whilst all non-
mmunized animals died by day 4 post-challenge, 80% of the
accinates showed a delay of around 48 h in the onset of death and
0% of them were protected. Therefore, this DNA/rMVA-VP2-VP5
accination conferred partial protection against a lethal challenge
ith BTV-4. In further studies, rMVA and cDNA expressing VP7
as included in the vaccination regime to improve the effective-
ess of the vaccine. Similar levels of virus neutralizing antibodies
ere stimulated with this vaccination regime but in addition VP2
nd VP7 speciﬁc BTV T-cell responses were detected in the vacci-
ated mice. In this study, whereas all unvaccinated animals died,
ice vaccinated with DNA/rMVA-VP2-VP5-VP7 did not show clin-cal signs of disease or viremia at any point after infection with the
irus, even by qRT PCR, so they were completely protected against
ethal BTV-4 challenge (Calvo-Pinilla et al., 2009b). Although this
ectored vaccine conferred sterile protection against homologousearch 182 (2014) 78–86
BTV-4 challenge, when this vaccine was  evaluated against the het-
erologous serotype BTV-8, only a delay of the disease was  observed
and therefore no heterotypic protection was conferred against a
different serotype.
In order to develop a BTV vaccine that elicits cross-protection
against other BTV serotypes, NS1 expression vaccine vectors were
tested (Calvo-Pinilla et al., 2012) since NS1 is one of the most
conserved proteins amongst BTV serotypes (Barratt-Boyes et al.,
1995). Previous studies to map  the location of BTV epitopes rec-
ognized by CTLs showed that NS1 was  recognized by CTL from
sheep and mice (Janardhana et al., 1999; Jones et al., 1996). On the
other hand, VP5 was  no longer included in the vaccination regime
because virus neutralizing antibody responses of animals vacci-
nated with VP2 and VP5 vectors were not signiﬁcantly higher than
those vaccinated with VP2 vaccine vectors. Moreover VP5 protein
is highly variable amongst serotypes so it was assumed the pro-
tein is not going to contribute to the cross-protection. It is known
that NS1 assembles into tubules (Hewat et al., 1992) and in our
studies it was observed that co-expression of VP2, VP7 and NS1 in
transfected BHK-21 cells generates aggregates containing the three
BTV proteins (Calvo-Pinilla et al., 2012). In general, aggregates are
protected from degradation, which allows them to remain intact
for interaction with antigen-presenting cells and their internaliza-
tion to appropriate MCH  class II-loading compartments, effectively
enhancing their presentation of T cells (De Temmerman et al.,
2011; Rosenberg, 2006). Therefore for further vaccination studies
in mice, DNA/rMVA-VP2-VP7-NS1 vectors were used to test pro-
tection against homologous BTV-4 or heterologous BTV-8 or BTV-1
challenges. Thus, all vaccinated mice were protected against clini-
cal signs and viremia following a lethal BTV-4 challenge (even no
BTV RNA was detectable by qRTPCR). Therefore DNA/rMVA-VP2-
VP7-NS1 induced a complete sterile protection in vaccinated mice
against homologous BTV-4.
For the heterologous challenges, mice were infected with
100 pfu of BTV-8 or BTV-1. All immunized animals were com-
pletely protected against lethal challenge with these heterologous
serotypes. In contrast, all the non-immunized mice died after chal-
lenge with BTV-8 or BTV-1 between day 5 and 6 or between days
6 and 7 respectively (Fig. 1A). Moreover no infectious virus was
detected in blood samples of immunized mice after infection with
BTV-8 or BTV-1 at any time of the experiment (Fig. 1B). Overall these
results show that cross-protection is achieved with DNA/rMVA-
VP2-VP7-NS1 vaccination against other serotypes of BTV. In terms
of immune response in the vaccinated animals, high levels of virus
neutralizing antibodies against BTV-4, but not against BTV-8 or
BTV-1, were detected, as expected (Fig. 1C). As well a speciﬁc T-
cell response activation was  seen in immunized animals, since
VP2, VP7 and NS1 proteins induced the expression of IFN- by
CD8+ T cells upon re-stimulation (Fig. 1 D) (Calvo-Pinilla et al.,
2012).
To analyze whether the combination of the three antigens
VP2, VP7 and NS1 from BTV-4 was essential for a complete pro-
tection against at least homologous challenge, DNA/rMVA-NS1,
DNA/rMVA-VP2-VP7 and DNA/rMVA-VP7-NS1 were tested sepa-
rately (unpublished data). Groups of mice were vaccinated with
each construct and four weeks after ﬁrst immunization animals
were challenged with same lethal dose of BTV-4 as in previ-
ous experiments. After infection, a delay in the onset of clinical
signs and lower viremia was  observed in all groups of vaccinated
mice in comparison with the control mice inoculated with empty
DNA/MVA. Immunization with vectors expressing NS1 alone did
not protect all vaccinated animals but protected 16% of the mice. In
mice immunized with DNA/rMVA-VP7-NS1, protection was better
and 25% of animals survived the challenge. Finally DNA/rMVA-VP2-
VP7 vaccination increased the survival rate of vaccinated animals
to 32%. These experiments conﬁrmed these vectors expressing VP2,
E. Calvo-Pinilla et al. / Virus Res
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Fig. 1. Vaccination with DNA/rMVA-VP2-VP7-NS1 protects IFNAR (−/−) mice
against homologous or heterologous BTV challenge. Six groups of six mice were
vaccinated either with DNAs and rMVAs expressing BTV-4 proteins (continue lines)
or with empty vectors (non-immunized, dotted lines). Two weeks after second vac-
cination mice were infected with 103 pfu of BTV-4 (blue), 100 pfu of BTV-8 (green) or
100  pfu of BTV-1 (purple). (A) Survival rates of the six groups of mice after challenge
during 12 days. (B) Viral load means (log pfu/ml) in blood of mice at different times
post-infection. SD are shown as error bars. (C) BTV-4 neutralizing antibodies titer in
immunized (blue) and non-immunized mice (orange). (D) Intracellular staining of
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wFN-,  in T CD8+ cells of immunized and non-vaccinated mice. Two  weeks after sec-
nd immunization spleens were harvested and splenocytes were stimulated with
0 g/ml of VP2, VP7 or NS1 proteins. Error bars show SD.
P7 and NS1 were necessary in combination for a total protection
gainst BTV-4 challenge. Interestingly, when DNA/rMVA-VP7-NS1
as tested against heterologous BTV-8 challenge, a survival rate of
5% was achieved for the vaccinated animals and then the hete-
otypic protection achieved was exactly the same as with the
omologous challenge (unpublished data). Host immune responses
nduced by VP7 and NS1 BTV-4 proteins had equal protective
ffect to protect animals against the same or different serotype,
emonstrating the cross-protection properties of these proteins.
rotective immunity against BTV is traditionally attributed to
he induction of virus neutralizing antibodies which was  not
enerated following vaccination with DNA/rMVA-VP7-NS1. These
esults suggested that cellular immune responses against VP7
nd NS1 proteins could play a role in virus clearance from the
ost.
In order evaluate the cross-protection induced by the VP2-
P7-NS1 vaccination strategy in a natural host, Marroquina lambs
ere immunized with DNA-VP2-VP7-NS1 (300 g/lamb) andearch 182 (2014) 78–86 83
rMVA-VP2-VP7-NS1 (3 × 107 pfu/lamb) from BTV-4 and chal-
lenged with 106.2 TCID50 of BTV-8 two weeks after the second
immunization. Viremia was analyzed and qRT-PCR data showed
that vaccinated animals presented lower levels of viremia than
non-immunized animals. White blood cell (WBC) count in non-
immunized lambs was at its lowest level on day 5 post-challenge
coinciding with the highest virus titers in blood. This is consistent
with previous studies showing BTV infection causes leukopenia in
ruminants (Foster et al., 1991). In contrast, immunized animals
maintained normal levels (7 × 109 cells/L) at day 5 post-infection
indicating that vaccinates were partially protected against BTV-8
infection. The absence of BTV-8-speciﬁc neutralizing antibodies in
the immunized sheep, suggested that the cell-mediated immunity
induced by the vaccination contributed to the partial heterotypic
protection observed. This aspect will be analyzed in sheep as it has
been already analyzed in the IFNAR (−/−) mice model.
Since the massive BTV-8 outbreak in Northern Europe occurred,
potential MVA  vaccines based on proteins from this serotype were
constructed and tested. In studies by Jabbar and co-workers, the
efﬁcacy of homologous rMVA/rMVA and heterologous DNA/rMVA
prime-boost vaccination regimes was compared in the IFNAR (−/−)
mouse model. These studies used vaccine constructs expressing
either VP2 alone, VP7 alone or a combination of VP2, VP5 and VP7
from BTV-8 (Jabbar et al., 2013). Although immunization with vec-
tors expressing VP7 alone did not protect IFNAR (−/−) mice against
BTV-8 challenge, vaccinated animals showed a delayed onset of
clinical signs and the survival time was slightly longer than in
the non-vaccinated mice. Moreover the study showed that both
rMVA/rMVA or DNA/rMVA prime boost vaccinations, expressing
either BTV-8 VP2 alone or a combination the three proteins, induced
protective immunity against BTV-8 challenge in mice. Very sim-
ilar levels of efﬁcacy of both vaccination regimes were shown.
Interestingly, complete protection was achieved with vaccine vec-
tors expressingVP2 alone. The two groups of mice vaccinated with
BTV-8 VP2 alone, using either a heterologous DNA/rMVA or homol-
ogous rMVA/rMVA strategy, were completely protected against
clinical signs of BTV infection, and all of them survived the chal-
lenge (Fig. 2A) and had no detectable viremia by plaque assay
(Fig. 2B). Only low levels of BTV RNA were detected in some indi-
viduals by qRT-PCR, as well as in mice vaccinated with the three
proteins. Herein, these DNA and MVA  vaccines expressing VP5
and VP7 did not improve the protection induced by BTV-8 VP2
alone. The additional expression of more BTV proteins was  nec-
essary to protect animals in the experiments described earlier, but
in this case the protein VP2 was expressed from BTV-8, indicat-
ing that there could be differences in immunogenicity between
same proteins of different serotypes. These results are consistent
with other vaccination studies performed with another orbivirus,
African horse sickness virus (AHSV), which showed that vaccina-
tion with a recombinant MVA  expressing the outer capsid protein
VP2 of AHSV protected IFNAR (−/−) mice against virulent AHSV
(Castillo-Olivares et al., 2011). In other studies, recombinant viruses
expressing BTV-8 VP2 alone were not enough to confer protec-
tion against challenge in mice; nevertheless the viral vectors used
in those studies were different from MVA. It is still not clear
why in some circumstances VP2 alone is enough to induce pro-
tective immunity but it is known that some antigens appear to
elicit better or worst immune response using different delivery
system.
2.4. Use of reverse genetics for vaccine development2.4.1. DISC (Disabled-Infectious-Single-Cycle) vaccines
Another approach which is also compatible with DIVA diag-
nostics is the development of disabled infectious single cycle
vaccines (DISC). These vaccines are based on the production of
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Fig. 2. Analysis of protection against BTV-8 after vaccination with DNA/rMVA or
rMVA/rMVA vectors expressing VP2, VP5 and VP7 proteins, VP7 alone or VP2 alone.
Groups of six mice were vaccinated with either DNA/rMVA or rMVA/rMVA express-
ing VP2, VP5 and VP7, VP7 alone or VP2 alone, and were challenged with BTV-8
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nd control mice after challenge with BTV-8. Each point represents the mean values
f  the viral titer of six animals and standard errors are shown as bars.
odiﬁed virus with a deletion in one or more genes that are essen-
ial for virus replication. In cancer therapy, DISC-Herpes simplex
irus encoding granulocyte macrophage colony stimulating fac-
or (GM-CSF) has demonstrated its immunotherapeutic potential
Ali et al., 2002; Rees et al., 2002). Recently, a BTV reverse genet-
cs technology to generate replication-deﬁcient BTV serotypes has
een developed (Boyce et al., 2008) making it possible the res-
ue of DISC viruses. This method is based on the introduction
f a lethal mutation in one of the genes essential for replica-
ion, such as the gene encoding the viral helicase VP6 protein
Matsuo et al., 2011). A BTV-1 DISC virus was generated and
sed to construct a defective re-assortant by replacing the seg-
ents encoding for VP2 and VP5 with those from BTV-8 thereby
reating BTV-1/8D1. Vaccination of sheep with these BTV-1 and
TV-1/8D1 DISC viruses prevented viraemia after homologous
hallenge with BTV-1 or BTV-8 respectively. Follow on studies
howed that vaccination of sheep with a combination of DISC
iruses induced a virus neutralizing antibody response against each
f the serotypes represented in the vaccine (BTV-2, BTV-4 and BTV-
) and were protected against clinical signs and viraemia (Celma
t al., 2013).earch 182 (2014) 78–86
2.4.2. Gene segment re-assortant vaccines based on attenuated
live BTV-6 virus
In a different use of reverse genetics, segments 2 (VP2) and 6
(VP5) of the live attenuated BTV-6 vaccine were exchanged for
those of BTV-1 and BTV-8, resulting in the generation of BTVac-1
and BTVac-8, respectively (van Gennip et al., 2012). Vaccination of
sheep with a single dose of these re-assortants induced a virus neu-
tralizing antibody response against the homologous serotype. After
challenge at three weeks post vaccination with cell-passaged viru-
lent BTV-8, vaccinated animals showed nearly no clinical reaction.
Furthermore, protection was similar between sheep vaccinated
with BTVac-1 and animals vaccinated with BTVac-8. These data
indicated that all sheep were partially protected from a challenge
with homologous and heterologous serotype. However, virus geno-
typing analyses of blood samples from vaccinated sheep at 14
days post-challenge revealed the presence of BTVac-1, BTVac-8 and
BTVac-6 but not the BTV-8 challenge virus suggesting a complete
clearance of the challenge virus infection. These two examples of
the use of reverse genetics showed the tremendous potential of
this technology for vaccine development. Further work is needed
to explore further the application of this strategy and also to address
any potential bio-safety risk associated with the exchange of gene
segments between vaccine and ﬁeld viruses.
3. Conclusion
When conventional BTV vaccines were used in the past,
serotype-speciﬁc control of bluetongue was achieved in response
to speciﬁc outbreaks. However in order to overcome disadvantages
of attenuated and inactivated vaccines, new effective recombinant
vaccines have been developed over the last two  decades. In addition
recombinant vaccines expressing conserved protective antigens in
order to generate an effective multivalent vaccine would reduce
the number of multiserotype vaccinations required, therefore pro-
viding a cost-effective product. Despite the major advances in the
understanding and prevention against BTV in trials with new gener-
ation vaccines, a commercial recombinant vaccine against this virus
remains elusive. Usually animal health policy requirements for
improved vaccines usually delays or precludes their implementa-
tion in the ﬁeld. Important advantages of new generation vaccines
comparing to conventional vaccines are the inherent safety and
the possibility to distinguish serologically infected from vaccinated
animals, which allow the control of the disease and surveillance.
Right surveillance of a disease is highly important to authorize the
safe movement of susceptible animals between affected and free
zones. Moreover, experimental vaccines are useful tools to better
understand the immune mechanisms activated in the animal to
counteract the virus. For both reasons, development of recombi-
nant vaccines against BTV is still essential nowadays.
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